anti cd123 cd3 bispecific antibody jnj 63709178

Drug Overview

The medication known as anti cd123 cd3 bispecific antibody jnj 63709178 (also identified as CNTO 9958) is a high-precision, investigational immunotherapy designed to treat aggressive blood cancers. It is a “first-in-class” Bispecific T-cell Engager (BiTE), constructed using the proprietary DuoBody® platform. Unlike traditional monoclonal antibodies that target a single marker, this bispecific antibody is engineered with two distinct “arms.” One arm is programmed to lock onto CD123 on leukemia cells, while the other arm grabs CD3 on T-cells, the body’s primary immune soldiers.

By acting as a molecular bridge, JNJ-63709178 physically forces an encounter between the immune system and the cancer. This “handcuffs” the T-cell to its target, triggering a lethal immune response against cells that would otherwise remain hidden.

• Generic Name: JNJ-63709178.
• Other Names: CD123-CD3 DuoBody, CNTO 9958.
• Drug Class: Bispecific Monoclonal Antibody / T-cell Engager.
• Target Antigens: CD123 (IL-3 receptor alpha) and CD3.
• Route of Administration: Intravenous (IV) or Subcutaneous (SC).
• FDA Approval Status: Investigational/Inactive. As of 2026, clinical development has been largely discontinued. While it reached Phase I, the program was halted due to severe immune over-activation (Cytokine Release Syndrome) and a lack of sufficient clinical benefit compared to newer candidates.

What Is It and How Does It Work? (Mechanism of Action)

The Molecular Targets: CD123 and CD3

To understand the drug’s power, one must look at the two proteins it targets. CD123 is highly overexpressed on Leukemic Stem Cells (LSCs)—the “roots” of the cancer that often cause recurrence. CD3 is a protein complex on T-cells essential for signaling the cell to attack.

Molecular Level Mechanisms

1. Dual-Antigen Engagement: Once infused, JNJ-63709178 seeks out a CD123-positive leukemia cell and a nearby T-cell, binding both simultaneously.
2. Formation of the Immunological Synapse: This bridge creates an artificial “synapse,” holding the two cells in such close proximity that the T-cell is forced to recognize the leukemia cell as a threat.
3. T-cell Activation: Binding to CD3 triggers a massive activation signal inside the T-cell, which then releases toxic proteins called perforins and granzymes.
4. Target Cell Lysis: The perforins poke holes in the leukemia cell membrane, while granzymes enter to shred the cell’s internal machinery, causing it to burst and die (lysis).
5. Selective Killing: The drug is designed to activate T-cells only when both arms are engaged, theoretically sparing healthy tissues that do not express CD123.

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for JNJ-63709178.

During its development, it was available only to patients in Phase I clinical trials (such as NCT02715011) for the following conditions:

• Relapsed or Refractory Acute Myeloid Leukemia (AML): For adults who failed to go into remission after standard chemotherapy or whose cancer returned.
• High-Risk Myelodysplastic Syndromes (MDS): Investigated for patients whose bone marrow was no longer producing healthy blood cells and was at risk of transforming into leukemia.

Dosage and Administration Protocols

Because the drug was discontinued during Phase I, there is no “Standard of Care” dose. The protocols established during research focused on finding the Maximum Tolerated Dose (MTD).

Clinical Efficacy and Research Results

The clinical results for JNJ-63709178 provided a roadmap for modern leukemia immunotherapy.

• Efficacy Data: In Phase I studies, the drug showed modest activity. Out of 62 patients, very few achieved a “Complete Remission.” Many saw a temporary drop in leukemia “blasts,” but the cancer often adapted and returned.
• Pharmacokinetic Issues: Scientists found the drug had a very short “half-life,” meaning it didn’t stay in the system long enough to maintain a sustained attack on the persistent leukemia stem cells.
• Safety Failure: The primary reason for discontinuation was a narrow “therapeutic window.” The dose required to kill the cancer was too close to the dose that caused permanent damage to healthy organs.

Safety Profile and Side Effects

The primary challenge for CD123/CD3 bispecifics is the intensity of the immune response. Because CD123 is found in small amounts on some healthy cells, collateral damage can be significant.

Common Side Effects (>15%):

• Cytokine Release Syndrome (CRS): The most dangerous side effect. As T-cells kill cancer, they release an explosion of inflammatory chemicals, causing high fevers, dangerously low blood pressure, and difficulty breathing.
• Fatigue and Pyrexia: Intense exhaustion and fever following infusions.
• Anemia and Thrombocytopenia: A severe drop in red blood cells and platelets as the drug impacts the bone marrow.

Serious Adverse Events:

• ICANS (Neurotoxicity): Manifests as confusion, tremors, loss of speech, or seizures.
• Hepatotoxicity: Elevation of liver enzymes, indicating an immune attack on liver tissue.
• Infusion Reactions: Severe allergic reactions immediately after starting the IV.
• Management Strategies: Doctors used Tocilizumab (an IL-6 blocker) to dampen the “cytokine storm” without stopping the cancer-killing activity.

Research Areas

In the realm of Stem Cell and Regenerative Medicine, JNJ-63709178 is viewed as a landmark “experimental tool.” CD123 is a critical marker for Hematopoietic Stem Cells (HSCs). Researchers are using data from this drug to solve the “Stem Cell Dilemma”: how to kill leukemic stem cells (LSCs) without destroying the healthy stem cells a patient needs for survival. Current 2026 research focuses on “Logic-Gated” bispecifics that only activate if they see two specific markers, ensuring that after the cancer is cleared, the patient’s bone marrow can regenerate a healthy blood system naturally.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD123 Expression Confirmation: A bone marrow biopsy to ensure the cancer expresses the target.
• Cardiac and Pulmonary Baseline: Essential due to the stress CRS puts on the heart and lungs.
• Baseline Neurological Exam: To identify early signs of neurotoxicity during treatment.

Precautions During Treatment:

• Mandatory Hospitalization: Patients must be hospitalized during the “Step-up” doses in a center with an Intensive Care Unit (ICU).
• Seizure Prophylaxis: Anti-seizure medications (like Levetiracetam) are often given before the dose to prevent neurological fits.

“Do’s and Don’ts” List:

• DO report any “shaking chills” immediately; these are often the first signs of a cytokine storm.
• DO stay within 30 minutes of a specialized cancer center for 4 weeks after your last dose.
• DON’T drive or operate heavy machinery for at least one week after a dose, as neurotoxicity can cause sudden confusion.
• DON’T ignore a mild headache; it can be the first warning sign of brain inflammation.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. JNJ-63709178 is an investigational agent that has been discontinued from active development. It is not approved by the FDA for any condition. Always consult with a qualified hematologist-oncologist regarding currently approved treatments or your eligibility for active clinical trials.